Literature DB >> 10081606

The order of exposure of tau to signal transduction kinases alters the generation of "AD-like" phosphoepitopes.

T B Shea1, C M Cressman.   

Abstract

1. The individual and sequential influence of protein kinase C (PKC), protein kinase A (PKA) and mitogen-activated protein kinase (MAP kinase) on human brain tau was examined. 2. A range of PKC concentrations generated certain phosphoepitopes common with paired helical filaments. These epitopes were masked by higher PKC concentrations, suggesting the presence of multiple tau phosphorylation sites for which PKC exhibited differing affinities and/or conformational alterations in tau induced by sequential PKC-mediated phosphorylation. 3. Prior phosphorylation by PKC enhanced the nature and extent of AD-like tau antigenicity generated by subsequent incubation with MAP kinase yet inhibited that generated by subsequent incubation with PKA. 4. Dephosphorylation of tau prior to incubation with kinases significantly altered the influence of individual and multiple kinase incubation on tau antigenicity in a site-specific manner, indicating that prior in situ phosphorylation events markedly influenced subsequent cell-free phosphorylation. 5. In addition to considerations of the potential impact of tau phosphorylation by individual kinases, these findings extend previous studies which indicate that tau antigenicity, and, presumably, its behavior in situ, is influenced by the sequential and convergent influences of multiple kinases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081606     DOI: 10.1023/a:1006977127422

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  41 in total

1.  Application of synthetic phospho- and unphospho- peptides to identify phosphorylation sites in a subregion of the tau molecule, which is modified in Alzheimer's disease.

Authors:  W K Liu; W T Moore; R T Williams; F L Hall; S H Yen
Journal:  J Neurosci Res       Date:  1993-02-15       Impact factor: 4.164

2.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.

Authors:  A Sengupta; Q Wu; I Grundke-Iqbal; K Iqbal; T J Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

3.  p44mpk MAP kinase induces Alzheimer type alterations in tau function and in primary hippocampal neurons.

Authors:  Q Lu; J P Soria; J G Wood
Journal:  J Neurosci Res       Date:  1993-07-01       Impact factor: 4.164

4.  p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected].

Authors:  M Goedert; E S Cohen; R Jakes; P Cohen
Journal:  FEBS Lett       Date:  1992-11-02       Impact factor: 4.124

5.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

Authors:  D P Hanger; K Hughes; J R Woodgett; J P Brion; B H Anderton
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

6.  Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.

Authors:  E M Mandelkow; G Drewes; J Biernat; N Gustke; J Van Lint; J R Vandenheede; E Mandelkow
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

7.  Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments.

Authors:  H K Paudel; J Lew; Z Ali; J H Wang
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

Review 8.  Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias.

Authors:  J Q Trojanowski; M L Schmidt; R W Shin; G T Bramblett; D Rao; V M Lee
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

9.  Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3.

Authors:  T J Singh; N Haque; I Grundke-Iqbal; K Iqbal
Journal:  FEBS Lett       Date:  1995-01-30       Impact factor: 4.124

10.  Phosphorylation of microtubule-associated protein tau: identification of the site for Ca2(+)-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles.

Authors:  B Steiner; E M Mandelkow; J Biernat; N Gustke; H E Meyer; B Schmidt; G Mieskes; H D Söling; D Drechsel; M W Kirschner; M Goedert; E Mandelkow
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

View more
  6 in total

1.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

2.  Phosphorylation of tau alters its association with the plasma membrane.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  2000-08       Impact factor: 5.046

Review 3.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

4.  Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Authors:  Michelle L Steinhilb; Dora Dias-Santagata; Tudor A Fulga; Daniel L Felch; Mel B Feany
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

Review 5.  While I Still Remember: 30 Years of Alzheimer's Disease Research.

Authors:  Thomas B Shea
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target.

Authors:  Sebastian S Oakley; Mahmoud B Maina; Karen E Marshall; Youssra K Al-Hilaly; Charlie R Harrington; Claude M Wischik; Louise C Serpell
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.